Exabis Library
Welcome to the e-CCO Library!
P526 Body mass index and response to TNF-α inhibitors in inflammatory bowel disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P526: A prediction model for successful increase of adalimumab dose intervals: analysis of the pragmatic open-label randomised controlled non-inferiority LADI trial
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P526: A prospective 52-week mucosal healing and deep remission assessment of small bowel and colonic Crohn's disease as detected by colon capsule endoscopy
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P526: Early sonographic response predicts long-term outcome in Crohn’s disease: A prospective cohort study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P526: Measurement of thiopurine metabolites concentrations after one week of treatment does not predict treatment failure in Inflammatory Bowel Disease patients
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P526: Social functioning, work-productivity and psychological assessment in a cohort of patients with inflammatory bowel disease: an observational study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P526: Survey of adherence to treatment in inflammatory bowel disease: ENADEII STUDY
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P527 A review of adverse events associated with immunosuppressive treatments in inflammatory bowel disease patients
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P527: Body image dissatisfaction is increased in inflammatory bowel disease compared with healthy matched controls but not diseased controls
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P527: Infliximab biosimilar switching program overseen by specialist pharmacist saves money, realises investment and optimises therapy
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P527: Investigating fatigue in vedolizumab-treated patients with ulcerative colitis or Crohn’s disease from a Belgian registry
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P527: Leucine-rich alpha 2 glycoprotein- A useful biomarker to discriminate mucosal healing in CRP-negative ulcerative colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P527: Low adalimumab serum levels at Week 4 provoke immunogenicity and influence therapy outcome in anti-TNF naïve Crohn’s disease patients
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P527: Telemedicine in IBD patients: results of a national survey of the Italian IBD patients’ association (AMICI Onlus)
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P528 Response to biologic therapy in operated Crohn’s disease patients
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P528: Effectiveness, Safety and Incremental Costs of Proactive Therapeutic Drug Monitoring of Infliximab in a Prospective Cohort of Inflammatory Bowel Disease Patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P528: Feasibility, satisfaction and machine learning analysis of factors influencing IBD patients’ trust in the mobile application Care4today IBD
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P528: Long-term outcome of ulcerative colitis patients responders to cyclosporine in the biological era
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P528: Patients’ perspectives on switching from reference infliximab to CT-P13 biosimilar in patients with inflammatory bowel disease: A 12-month prospective observational cohort study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P528: Reducing intravenous monoclonal antibody observation times without compromising patient safety; a single-centre observational study.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM